drugset / Trial / NCT04260464
Renal Impairment Study of PF-06700841
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.
Timeline
- Start
- 2020-07-03
- Primary completion
- 2022-05-04
- Completion
- 2022-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brepocitinib | Small molecule | 30 mg | Oral |